cHL

This page shows the latest cHL news and features for those working in and with pharma, biotech and healthcare.

Keytruda hits primary endpoint in confirmatory lymphoma trial

CHL is, in comparison to Keytruda’s other indications, not quite as important. ... That includes evaluating Keytruda in combination with chemotherapy in children and young adults in first-line cHL and in the post-Adcetris treatment setting.

Latest news

Innovent gears up for PD-1 inhibitor launch in China

cHL) in December.
China’s BeiGene takes PD-1 antibody into pivotal trials

The single-arm trial enrolled 70 cHL patients who had failed autologous stem cell transplantation (ASCT) – a primary treatment for the cancer – or were ineligible for the procedure.
Merck suspends two Keytruda trials after patient deaths

Earlier this year Keytruda was approved for classical Hodgkin lymphoma (cHL) - its first non-solid tumour indication - and expanding into blood cancers is a key target for Merck.
Keytruda and Opdivo backed for new uses in Europe

cHL), shortly after the FDA cleared the drug for the same blood cancer in the US. ... BMS' Opdivo (nivolumab) - which is already approved in the EU for cHL - was given the nod for the treatment for adults with squamous cell cancer of the head and neck
Keytruda claims first blood cancer OK from FDA

Merck &Co wins US approval for its haematological cancer treatment. Merck &Co has won FDA clearance for its PD-1 inhibitor Keytruda in classical Hodgkin lymphoma (cHL), the first green light ... The US regulator gave a conditional approval to Keytruda

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Chinese biotech’s global ambitions

CDA). The company is filing first for patients with relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) – a niche indication not yet taken in China by Keytruda and Opdivo, which